SYRS - サイロス・ファ―マシュ―ティカルズ (Syros Pharmaceuticals Inc.)

SYRSのニュース

   Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/16 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020. The fireside chat will be available for on-demand viewing on the In
   Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2020/11/05 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2020, and provided an update on recent accomplishments and upcoming events. “We are making great progress on the three pillars underlying our corporate strategy: advancing SY-1425 in RARA-positive patients, building on our leadership in CDK7 inhibition, and continuing to invest
   Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting  2020/11/04 15:12:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha (RARα) agonist, at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-
   Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020  2020/10/29 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 1088286. A webcast
   Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Hold at ValuEngine  2020/10/25 06:46:41 Dakota Financial News
Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports. Other analysts also recently issued reports about the stock. JMP Securities raised their target price on shares of Syros Pharmaceuticals from $16.00 to $20.00 and […]
   Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/16 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020. The fireside chat will be available for on-demand viewing on the In
   Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2020/11/05 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2020, and provided an update on recent accomplishments and upcoming events. “We are making great progress on the three pillars underlying our corporate strategy: advancing SY-1425 in RARA-positive patients, building on our leadership in CDK7 inhibition, and continuing to invest
   Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting  2020/11/04 15:12:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha (RARα) agonist, at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-
   Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020  2020/10/29 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 1088286. A webcast
   Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Hold at ValuEngine  2020/10/25 06:46:41 Dakota Financial News
Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports. Other analysts also recently issued reports about the stock. JMP Securities raised their target price on shares of Syros Pharmaceuticals from $16.00 to $20.00 and […]
   Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Hold at ValuEngine  2020/10/25 06:46:41 Dakota Financial News
Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports. Other analysts also recently issued reports about the stock. JMP Securities raised their target price on shares of Syros Pharmaceuticals from $16.00 to $20.00 and […]
   Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting  2020/10/24 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in pa
   Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $49,638.75 in Stock  2020/10/22 05:08:49 Stock Observer
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 5,673 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $8.75, for a total transaction of $49,638.75. Following the completion of the transaction, the director now owns 335,201 shares in the company, valued […]
   Richard A. Young Sells 5,673 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock  2020/10/21 09:02:46 Zolmax News
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 5,673 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $8.75, for a total value of $49,638.75. Following the sale, the director now directly owns 335,201 shares in the company, valued at […]
   Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting  2020/10/09 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with select solid tumors. The data will be presented in a poster session at the 32nd EORTC-NCI-AACR Symposium, taking plac

calendar